CompletedNot Applicable

Patient-Centric Innovation: Superior Vena Cava Approach in Zero-Fluoroscopy

China31 participantsStarted 2022-10-01

Plain-language summary

This study aims to evaluate the viability and therapeutic efficacy of zero-fluoroscopy radiofrequency catheter ablation (RFCA) using the superior vena cava (SVC) approach in patients with atrioventricular nodal reentrant tachycardia (AVNRT). The study compares outcomes between the SVC approach and the conventional inferior vena cava (IVC) approach. Patients diagnosed with AVNRT who underwent RFCA between June 2022 and October 2022 were retrospectively analyzed. The primary outcome measure is the non-inducibility of AVNRT, while secondary outcomes include postoperative recovery time and complication rates. The study seeks to provide a safer and more efficient RFCA method, enhancing patient recovery by minimizing radiation exposure and optimizing catheter access routes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged \>18 years. * Diagnosed with atrioventricular nodal reentrant tachycardia (AVNRT). * Underwent radiofrequency catheter ablation (RFCA) at our institution between June 2022 and October 2022. * Experienced at least one episode of AVNRT during transesophageal atrial pacing (TEAP) and programmed stimulation. * Provided informed consent for the procedure and data collection. Exclusion Criteria: * AVNRT attributed to reversible causes, such as acute myocarditis or recent cardiac surgery. * Presence of other types of tachycardias (e.g., atrial tachycardia, Wolff-Parkinson-White syndrome, ventricular tachycardia). * Inability to abstain from pharmacological interventions for at least five half-lives of the medication prior to TEAP. * Contraindications for the use of conscious sedation or local anesthesia. * Severe comorbidities that would interfere with study participation or follow-up. * Patients who are pregnant or lactating. * Previous RFCA procedures for AVNRT within the past six months.

What they're measuring

Non-inducibility of Atrioventricular Nodal Reentrant Tachycardia (AVNRT)

Timeframe: During the procedure

Recurrence of supraventricular tachycardia

Timeframe: Within 1 year post-procedure

Trial details

NCT IDNCT06492499

SponsorNing Zhou

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-10-01